NCCN Receives $4 Million ncology Research Grant from Wyeth
The News Review:
- NCCN Receives $4 Million ncology Research Grant from Wyeth
- Groundbreaking held for new Pennington research center
- LETTER: Say no to new clinical research regulations
- Red tape is killing UK clinical research warn academics
- bioRASI Names Gary W. Thompson Vice President of Business Development
- MDS Pharma Services Appoints Dr. Jessica Liu to Lead Clinical …
NCCN Receives $4 Million ncology Research Grant from Wyeth
PR Newswire (press release) NY
Investigation of combination therapy with cytotoxics targeted therapies biologic agents and radiation therapy based on hypothesis generating preclinical studies. Identification of biomarkers and molecular imaging that can be used to assess mTR inhibition. The NCCN ncology Research Program (RP) facilitates all phases of clinical research by identifying clinical investigators and initiating trials at NCCN Member Institutions. The RP draws on the expertise of investigators at 21 of the world’s leading cancer centers and establishes collaborations with pharmaceutical and biotech companies in order to advance therapeutic options for patients with cancer. About the National Comprehensive Cancer NetworkThe National Comprehensive Cancer Network (NCCN) a not-for-profit alliance of 21 of the world’s leading cancer centers is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients clinicians and other health care decision-makers.
Groundbreaking held for new Pennington research center
WBXH LA
Governor Bobby Jindal along with state legislators approved the funding last year. Wednesday they broke ground on the new clinical research building that will use about half of the $50 million allotment. It will be a 90000-square foot facility to expand clinical trials so that researchers can get more grants and answer more scientific questions. The expansion comes as Governor Jindal warns of serious higher education cuts on the horizon. “No I don't think this will be the last investment of its kind” he said. “We're going to have to continue to move the state forward and we'll do that.
LETTER: Say no to new clinical research regulations
SouthCoastToday.com MA
Mark Montigny regarding clinical research trials in Massachusetts (”Montigny unhappy with draft pharmaceutical gift ban” Dec. 11) maybe he and Gov. Deval Patrick should look elsewhere to impose new regulations (Section 14 Chapter 111N of S2863). I have worked in clinical research for the last 10 years and this regulation can cause pharmaceutical companies to eliminate our site (and many in Boston) from participating in clinical trials. The state of Massachusetts (particularly the northeast area) has some of the best clinical research centers and does a tremendous amount of clinical studies with all types of diseases such as cancer asthma allergies migraines obesity arthritis (osteo and rheumatoid) women’s health gastrointestinal disorders and many many more diseases that need the help of new medication to control or eliminate the disease.
Red tape is killing UK clinical research warn academics
Pharma Times UK
Meanwhile the number of studies seeking ethical approval has fallen by 30 per cent and the Medicines and Healthcare products Regulatory Agency has logged a 50% reduction in the number of non-commercial trial authorisations. ver the same period since 2004 other European agencies have registered a stable or higher number of trials the academics add. For smaller biotechnology companies they note transferring studies abroad is less feasible than for the pharmaceutical industry.
bioRASI Names Gary W. Thompson Vice President of Business Development
SYS-CN Media NJ
In every area he has proved himself a verystrong leader; likeable knowledgeable and well trusted by the industry. In conjunction with the opening of several new offices around the worldGary will lead our efforts providing optimal solutions to our clients’clinical development programs. Prior to joining bioRASI Gary Thompson served as the Vice President ofBusiness Development for Bio Pharma Services as well as the Head ofBusiness Development for Veeda Clinical Research one of the fastestgrowing CRs in India. Previously he has held leading businessdevelopment positions with major CRs including Bioanalytical Systems Inc. (BASi) PPD Pharmaco Inc. and Phoenix International Life Sciences. “I am very excited about joining the bioRASI Team and working with some ofthe most dedicated knowledgeable and accomplished professionals in theindustry” said Mr.
Related from Sales-monster: Pacific Life Annuities & Mutual Funds Division Names New …
MDS Pharma Services Appoints Dr. Jessica Liu to Lead Clinical …
PharmaLive.com (press release) PA
Liu brings many years of extensive and relevant global experience in medicine clinical research and the pharmaceutical industry to this important position” said MDS Pharma Services President David Spaight. “Her appointment reflects our commitment to provide the highest levels of quality and service to our clients in a region that has emerged as a key arena for global clinical research. Her clinical research experience encompasses a number of therapeutic areas in which MDS Pharma Services specializes including oncology diabetes and infectious diseases. ”Prior to joining MDS Pharma Services Dr. Liu was with Bristol-Myers Squibb (BMS) for ten years most recently in Brussels where she managed international BMS projects.
Written by admin on January 15th, 2009 with
no comments.
Read more articles on News.